The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BENEDETTI, F.
* Articles by SMERALDI, E.
* Search for Related Content
PubMed
* Articles by BENEDETTI, F.
* Articles by SMERALDI, E.
Related Collections
* Neurotransmitters
* Depression
* Genetics
Am J Psychiatry 157:1887-1888, November 2000
© 2000 American Psychiatric Association


Letter to the Editor

Dr. Benedetti and Colleagues Reply

FRANCESCO BENEDETTI, M.D., ALESSANDRO SERRETTI, M.D., CRISTINA COLOMBO, M.D., EURIDICE CAMPORI, M.D., BARBARA BARBINI, M.D., DANIELA DI BELLA, M.D., and ENRICO SMERALDI, M.D.
Milan, Italy

To the Editor: We thank Dr. Nobile and her colleagues for commenting on our data and raising issues for further research. The possibility that a different pattern of 5-HT activity may condition different responses to both pharmacological and chronobiological antidepressant treatments links with current research on 5-HT and the regulation of circadian rhythmicity (1) and on the dimension of cyclicity in mood disorders. Given the heterogeneity of mood disorders, the possibility of defining a kind of "serotonergic depression" (i.e., due to some kind of serotonergic malfunction and thus responding to serotonergic treatment) is of theoretical and clinical relevance.

A caveat is necessary, however. Given the interplay between neurotransmitter systems, clinical response to a treatment acting on one system does not imply a dysfunction of that system. In these respects, the data cited by Dr. Nobile et al. in depressed adolescents are the only findings available to support a 5-HT dysfunction in patients homozygotic for the long/long variant of the promoter of the 5-HT transporter. This new research area is still highly controversial; seasonal fluctuations in 5-HT blood levels have been described in subjects with the long/long variant (2), whereas seasonal affective disorder has shown a higher prevalence in subjects homozygotic for the short/short variant (3). A study of delusional depression showed different responses depending on genotype when patients were treated with fluvoxamine alone but not when fluvoxamine was combined with pindolol (4). These data support a role for self-inhibitory autoreceptors (and not only for the carrier) in determining response differences among genotypes and show that patients with the short/short variant can actually respond to combined therapies acting on 5-HT pathways. Finally, the short allele has been associated with higher anxiety levels in normal subjects and depressed patients (5), and anxious depression is known to show a less favorable response to treatment than melancholic depression. This suggests the presence of complex relationships among the 5-HT carrier genotype, treatment response, and psychopathology that are not limited to patients with the long/long genotype.

Notwithstanding the pioneering importance of every study in the field, additional research seems necessary before we can draw firm conclusions about the relationship between the 5-HT-transporter promoter genotype and the characteristics of mood disorders.

References

  1. Morin LP: Serotonin and the regulation of mammalian circadian rhythmicity. Ann Med 1999; 31:12–33[Medline]
  2. Hanna GL, Himle JA, Curtis GC, Koram DQ, Weele JV, Leventhal BL, Cook EH Jr: Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 1998; 18:102–111[CrossRef][Medline]
  3. Rosenthal NE, Mazzanti CM, Barnett RL, Hardin TA, Turner EH, Lam GK, Ozaki N, Goldman D: Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 1998; 3:175–177[CrossRef][Medline]
  4. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3:508–511[CrossRef][Medline]
  5. Serretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E: Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry 1999; 3:280–283[CrossRef]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BENEDETTI, F.
* Articles by SMERALDI, E.
* Search for Related Content
PubMed
* Articles by BENEDETTI, F.
* Articles by SMERALDI, E.
Related Collections
* Neurotransmitters
* Depression
* Genetics


Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org